DOVATO 50-300 MG TABLET

dolutegravir sodium and lamivudine
$105.2870per EA

Strength

50; 300 mg/1; mg/1

NDC

49702024633

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

1/1/2026

Approval Type

New Drug (NDA)

FDA Application

NDA211994

On Market Since

4/8/2019

Pharmacological Classes

HIV Integrase Inhibitors
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Multidrug and Toxin Extrusion Transporter 1 Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Organic Cation Transporter 2 Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+5.0%

1Y

+5.3%

3Y

N/A

5Y

N/A

All

+9.6%